R&D | October 29, 2025
Orion secures license to Abzena’s next-generation cancer antibody
The antibody was designed and developed at Abzena’s Cambridge, UK,
The antibody was designed and developed at Abzena’s Cambridge, UK,
The event will be attended by 35,000+ industry professionals
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Expanding US operations to address the increased demand for API development and manufacturing
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Subscribe To Our Newsletter & Stay Updated
